MAP3K8/COT/Tpl2

MAP3K8, also known as COT or Tpl2, is a serine/threonine kinase that regulates MAPK signaling cascades, primarily through activation of MEK1/2 and ERK1/2^[1][2]. Mechanistically, MAP3K8 modulates inflammatory responses by controlling the translation and stability of cytokine mRNAs in Toll-like receptor-activated macrophages, including TNFα, IL-6, and KC^[2][3]. In immune cells, MAP3K8 influences Th1 differentiation by inhibiting IL-12 production and shaping adaptive responses. Compared with other MAP3Ks, MAP3K8 exhibits isoform-specific regulation of Akt-mTOR-p70 S6k signaling, fine-tuning TLR-mediated responses^[3]. Disease models demonstrate MAP3K8’s involvement in cancer, metabolic inflammation, and viral infections; it drives androgen depletion-independent prostate cancer growth, contributes to obesity-induced adipose tissue inflammation, and is transcriptionally repressed during coronavirus infection^[4][5][6]. In liver and kidney injury models, MAP3K8 deficiency reduces sterile inflammatory damage and apoptosis, highlighting its pathological significance^[7][8]. Pharmacological inhibition of MAP3K8 suppresses pro-inflammatory cytokine production in human cytotoxic T lymphocytes and epithelial cells, though current tool compounds show limited potency, indicating a need for improved inhibitors for therapeutic applications^[9][10][11]. Collectively, MAP3K8 serves as a critical node connecting MAPK signaling, inflammatory regulation, and disease-specific cellular responses, distinguishing it functionally from related MAP3K isoforms^[12][13].